marked.bio

IDH1/2 inhibitor · small molecule

LY3410738

2 active trials, targeting IDH1/2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
IDH1/2 mutation 2 2 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of LY3410738.

  1. Eli Lilly 2

Trials

2 of 2 trials shown

  1. Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

    Active, not recruiting Phase 1 Eli Lilly Started 2020Primary completion 2023-07 NCT04603001

    LY3410738venetoclaxazacitidine

    Advanced IDH mutant hematologic malignancy including:

    IDH1/2 mutationAcute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)

  2. Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

    Active, not recruiting Phase 1 Eli Lilly Started 2020Primary completion 2023-07 NCT04521686

    LY3410738gemcitabinecisplatindurvalumab

    Evidence of IDH1 R132 mutation (any solid tumor) or circulating tumor DNA IDH2 R140 or IDH2 R172 mutation (chol…

    IDH1/2 mutationCholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor